Proteome Sciences PLC Net Assets

Latest as of December 2025: GBX-9.53 Million GBX ≈ $-1.16K USD

Proteome Sciences PLC net assets. Based on the latest financial reports, Proteome Sciences PLC (PRM) has net assets worth GBX-9.53 Million GBX (≈ $-1.16K USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX8.26 Million ≈ $1.00K USD) and total liabilities (GBX17.79 Million ≈ $2.16K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Proteome Sciences PLC equity growth rate to track the company's year-over-year net asset growth rate.

Key Net Assets Metrics

Metric Value
Current Net Assets GBX-9.53 Million
% of Total Assets -115.46%
Annual Growth Rate N/A
5-Year Change -100.01%
10-Year Change -100.0%
Growth Volatility 590.67

Net Assets of Proteome Sciences PLC (1994–2025)

Net assets of Proteome Sciences PLC from 1994 to 2025. This chart illustrates how Proteome Sciences PLC's net assets have evolved over time, based on quarterly financial data. See PRM net asset quality index to measure how much of total assets are equity-financed.

Annual Net Assets for Proteome Sciences PLC (1994–2025)

The table below shows the annual net assets of Proteome Sciences PLC from 1994 to 2025. For live market cap and overall valuation, see market cap of Proteome Sciences PLC.

Year Net Assets Change
2025-12-31 GBX-9.53 Million
≈ $-1.16K		 -46.27%
2024-12-31 GBX-6.52 Million
≈ $-792.81		 -112.52%
2023-12-31 GBX-3.07 Million
≈ $-373.04		 -100.00%
2022-12-31 GBX69.26 Billion
≈ $8.43 Million		 -1.12%
2021-12-31 GBX70.04 Billion
≈ $8.52 Million		 +4.72%
2020-12-31 GBX66.88 Billion
≈ $8.14 Million		 +1.86%
2019-12-31 GBX65.66 Billion
≈ $7.99 Million		 +2.95%
2018-12-31 GBX63.78 Billion
≈ $7.76 Million		 -3.39%
2017-12-31 GBX66.02 Billion
≈ $8.03 Million		 -93.97%
2016-12-31 GBX1.09 Trillion
≈ $133.11 Million		 +1561.08%
2015-12-31 GBX65.86 Billion
≈ $8.01 Million		 -0.14%
2014-12-31 GBX65.96 Billion
≈ $8.03 Million		 +3.14%
2013-12-31 GBX63.95 Billion
≈ $7.78 Million		 +8342750.20%
2012-12-31 GBX-766.53K
≈ $-93.26		 -123.24%
2011-12-31 GBX3.30 Million
≈ $401.39		 -54.30%
2010-12-31 GBX7.22 Million
≈ $878.34		 +178.14%
2009-12-31 GBX-9.24 Million
≈ $-1.12K		 -64.26%
2008-12-31 GBX-5.62 Million
≈ $-684.28		 -159.77%
2007-12-31 GBX-2.17 Million
≈ $-263.42		 -183.66%
2006-12-31 GBX2.59 Million
≈ $314.88		 -67.04%
2005-12-31 GBX7.85 Million
≈ $955.24		 -10.82%
2004-12-31 GBX8.80 Million
≈ $1.07K		 -25.67%
2003-12-31 GBX11.84 Million
≈ $1.44K		 +0.02%
2002-12-31 GBX11.84 Million
≈ $1.44K		 +371.94%
2001-12-31 GBX2.51 Million
≈ $305.27		 -4.96%
2000-12-31 GBX2.64 Million
≈ $321.21		 +2414.29%
1999-12-31 GBX105.00K
≈ $12.78		 -89.82%
1998-12-31 GBX1.03 Million
≈ $125.44		 -64.05%
1997-12-31 GBX2.87 Million
≈ $348.95		 +793.46%
1996-12-31 GBX321.00K
≈ $39.06		 -76.24%
1995-12-31 GBX1.35 Million
≈ $164.38		 +600.37%
1994-12-31 GBX-270.00K
≈ $-32.85		 0.00%
1994-10-31 GBX-270.00K
≈ $-32.85		 --

Equity Component Analysis

This analysis shows how different components contribute to Proteome Sciences PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 6873600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Proteome Sciences PLC Net Assets Breakdown (December 2025)

Proteome Sciences PLC net assets breakdown by equity component as of December 2025.

Component Amount Percentage
Common Stock GBX2.95 Million %
Other Comprehensive Income GBX4.81 Million %
Other Components GBX51.47 Million %
Total Equity GBX-9.53 Million 100.00%

Proteome Sciences PLC Competitors by Market Cap

The table below lists competitors of Proteome Sciences PLC ranked by their market capitalization.

Company Market Cap
Bumrungrad Hospital Public Company Limited
F:BZ7A
 $58.95K
Fadel Partners Inc
LSE:FADL
 $59.08K
Serinus Energy
LSE:SENX
 $59.54K
Digitalbox PLC
LSE:DBOX
 $59.54K
Trafalgar New Homes Plc
LSE:TRAF
 $57.39K
Philipp Holzmann AG
DU:HOZ
 $57.22K
Harmony Energy Income Trust PLC
LSE:HEIT
 $57.20K
Bisichi Mining PLC
LSE:BISI
 $57.16K

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Proteome Sciences PLC's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from -6,516,000 to -9,531,000, a change of -3,015,000.
  • Net loss of 3,061,000 reduced equity.
  • Other comprehensive income decreased equity by 10,608,001.
  • Other factors increased equity by 10,654,001.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income GBX-3.06 Million -32.12%
Other Comprehensive Income GBX-10.61 Million -111.3%
Other Changes GBX10.65 Million +111.78%
Total Change GBX- %

Book Value vs Market Value Analysis

This analysis compares Proteome Sciences PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1994-10-31 GBX0.00 GBX1.35 x
1994-12-31 GBX0.00 GBX1.35 x
1996-12-31 GBX0.00 GBX1.35 x
1997-12-31 GBX0.04 GBX1.35 x
1998-12-31 GBX0.01 GBX1.35 x
1999-12-31 GBX0.00 GBX1.35 x
2000-12-31 GBX0.03 GBX1.35 x
2001-12-31 GBX0.03 GBX1.35 x
2002-12-31 GBX0.11 GBX1.35 x
2003-12-31 GBX0.10 GBX1.35 x
2004-12-31 GBX0.07 GBX1.35 x
2005-12-31 GBX0.06 GBX1.35 x
2006-12-31 GBX0.02 GBX1.35 x
2007-12-31 GBX-0.02 GBX1.35 x
2008-12-31 GBX-0.04 GBX1.35 x
2009-12-31 GBX-0.07 GBX1.35 x
2010-12-31 GBX0.04 GBX1.35 x
2011-12-31 GBX0.02 GBX1.35 x
2012-12-31 GBX0.00 GBX1.35 x
2013-12-31 GBX285.47 GBX1.35 x
2014-12-31 GBX282.13 GBX1.35 x
2015-12-31 GBX270.59 GBX1.35 x
2016-12-31 GBX274.36 GBX1.35 x
2017-12-31 GBX216.49 GBX1.35 x
2018-12-31 GBX211.92 GBX1.35 x
2019-12-31 GBX218.27 GBX1.35 x
2020-12-31 GBX222.90 GBX1.35 x
2021-12-31 GBX228.76 GBX1.35 x
2022-12-31 GBX221.00 GBX1.35 x
2023-12-31 GBX-0.01 GBX1.35 x
2024-12-31 GBX-0.02 GBX1.35 x
2025-12-31 GBX-0.03 GBX1.35 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Proteome Sciences PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 0.00%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -81.50%
  • • Asset Turnover: 0.45x
  • • Equity Multiplier: 0.00x
  • Recent ROE (0.00%) is above the historical average (-64.03%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1994 0.00% 0.00% 0.00x 0.00x GBX7.00K
1994 0.00% 0.00% 0.00x 0.00x GBX7.00K
1996 0.00% 0.00% 0.00x 0.00x GBX-1.57 Million
1997 -52.20% 0.00% 0.00x 1.19x GBX-1.78 Million
1998 -179.53% 0.00% 0.00x 1.84x GBX-1.95 Million
1999 -1171.43% 0.00% 0.00x 7.64x GBX-1.24 Million
2000 -53.22% 0.00% 0.00x 1.60x GBX-1.67 Million
2001 -79.05% 0.00% 0.00x 1.50x GBX-2.23 Million
2002 -34.71% -2397.66% 0.01x 1.17x GBX-5.29 Million
2003 -57.25% -3987.77% 0.01x 1.22x GBX-7.97 Million
2004 -59.06% -7125.02% 0.01x 1.17x GBX-6.08 Million
2005 -87.84% -42572.25% 0.00x 1.22x GBX-7.68 Million
2006 -217.84% -8233.93% 0.01x 2.47x GBX-5.90 Million
2007 0.00% -1977.47% 0.04x 0.00x GBX-5.04 Million
2008 0.00% -544.38% 0.13x 0.00x GBX-4.06 Million
2009 0.00% -307.10% 0.21x 0.00x GBX-3.09 Million
2010 63.21% 45.72% 0.64x 2.16x GBX3.84 Million
2011 -119.96% -387.53% 0.09x 3.31x GBX-4.29 Million
2012 0.00% -368.93% 0.17x 0.00x GBX-4.18 Million
2013 -0.01% -147.39% 0.00x 24.26x GBX-5.54 Billion
2014 -0.01% -228.52% 0.00x 22.80x GBX-5.96 Billion
2015 0.00% -144.42% 0.00x 18.73x GBX-5.98 Billion
2016 0.00% -83.09% 0.00x 18.70x GBX-6.49 Billion
2017 0.00% -73.88% 0.00x 17.73x GBX-6.39 Billion
2018 0.00% -43.06% 0.00x 18.12x GBX-6.26 Billion
2019 0.00% 3.22% 0.00x 17.70x GBX-6.44 Billion
2020 0.00% 6.26% 0.00x 20.51x GBX-6.58 Billion
2021 0.00% 1.41% 0.00x 20.05x GBX-6.91 Billion
2022 0.00% 17.03% 0.00x 22.17x GBX-6.83 Billion
2023 0.00% -48.59% 0.44x 0.00x GBX-2.14 Million
2024 0.00% -69.70% 0.53x 0.00x GBX-2.75 Million
2025 0.00% -81.50% 0.45x 0.00x GBX-2.11 Million

Industry Comparison

This section compares Proteome Sciences PLC's net assets metrics with peer companies in the Diagnostics & Research industry.

Industry Context

  • Industry: Diagnostics & Research
  • Average net assets among peers: $349,563,657
  • Average return on equity (ROE) among peers: -69.28%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Proteome Sciences PLC (PRM) GBX-9.53 Million 0.00% N/A $57.40K
Abingdon Health Plc (ABDX) $6.43 Million -330.57% 0.99x $274.94K
ANGLE plc (AGL) $909.00K -104.62% 0.42x $94.18K
genedrive plc (GDR) $8.86 Million -2.75% 0.18x $119.01K
Integrated Diagnostics Holdings PLC (IDHC) $2.40 Billion 20.91% 0.43x $267.41 Million
LungLife AI Inc (LLAI) $-3.10 Million 0.00% 0.00x $15.48K
Oxford Biodynamics PLC (OBD) $13.58 Million -31.76% 0.13x $53.51K
Verici Dx Plc (VRCI) $19.62 Million -36.19% 0.03x $39.59K

About Proteome Sciences PLC

LSE:PRM UK Diagnostics & Research
Market Cap
$57.40K
GBX471.73 Million GBX
Market Cap Rank
#31647 Global
#1180 in UK
Share Price
GBX1.35
Change (1 day)
-7.56%
52-Week Range
GBX1.28 - GBX3.51
All Time High
GBX22.25
Categories
Companies in UK Diagnostics & Research
About

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in pla… Read more